Charles Swanton | |
---|---|
![]() Swanton in 2018 | |
Born | Robert Charles Swanton 1972 (age 52–53) [1] |
Education | St Paul's School, London |
Alma mater | University College London (MD, PhD) |
Awards | Ellison–Cliffe Lecture (2017) EMBO Member (2017) |
Scientific career | |
Fields | Cancer evolution [2] |
Institutions | Francis Crick Institute University College London |
Thesis | Viral cyclin disruption of mammalian cell cycle control mechanisms (1998) |
Doctoral advisor | Nic Jones |
Website | www |
Robert Charles Swanton is a British physician scientist specialising in oncology and cancer research. Swanton is a senior group leader at London's Francis Crick Institute, [3] Royal Society Napier Professor in Cancer [4] and thoracic medical oncologist at University College London [5] and University College London Hospitals, [6] [7] co-director of the Cancer Research UK (CRUK) Lung Cancer Centre of Excellence, and Chief Clinician of Cancer Research UK. [8] [9]
![]() | This section needs expansion. You can help by adding to it. (June 2024) |
Swanton was born in Poole, Dorset. As of 2017, his father Robert Howard Swanton (MD, FRCP) was a consultant cardiologist at UCL. [10]
Swanton was educated at St Paul's School, London [1] and completed his PhD in 1999 [11] at what was then the Imperial Cancer Research Fund Laboratories (now the Francis Crick Institute) and his Cancer Research UK clinician scientist/medical oncology training in 2008. [7]
Swanton has combined [ when? ] his laboratory research with clinical duties as co-director of the CRUK Lung Cancer Centre, focussed on how tumours evolve over space and time. [7] He has helped to define the branched evolutionary histories of solid tumours, processes that drive cancer cell-to-cell variation in the form of new cancer mutations or chromosomal instabilities, and the impact of such cancer diversity on effective immune surveillance and clinical outcome. [2] [7] [12] [13]
As of 2018, Swanton has been a co-founder of Achilles Therapeutics [14] with Sergio Quezada, Karl Peggs and Mark Lowdell. Achilles Therapeutics is a UCL/CRUK and Francis Crick Institute [15] biotechnology company funded by Syncona [16] that develops adoptive T cell therapies targeting clonal/truncal neo-antigens present in every tumour cell to limit drug resistance and tumour evolution.[ citation needed ]
![]() | This section needs expansion. You can help by adding to it. (June 2024) |
"All text published under the heading 'Biography' on Fellow profile pages is available under Creative Commons Attribution 4.0 International License." -- "Terms, conditions and policies | Royal Society". Archived from the original on 11 November 2016. Retrieved 27 June 2018.{{cite web}}
: CS1 maint: bot: original URL status unknown (link)
This article incorporates text available under the CC BY 4.0 license.